Molecular Analysis of 150 Lung Adenocarcinoma (LUNG-EST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02843711|
Recruitment Status : Unknown
Verified July 2016 by Hospices Civils de Lyon.
Recruitment status was: Active, not recruiting
First Posted : July 26, 2016
Last Update Posted : July 26, 2016
LUNG-EST is a retrospective study including 152 patients who benefit from lung surgery during the years 2012 to 2013 at Hospices civils de Lyon and with a diagnosis of lung adenocarcinomas. For all patients, clinical data and histopathological data are available. The objective of this study is to characterize these lung adenocarcinomas by the LungCarta Panel using the mass spectrometry array Sequenom. This panel could identify 214 DNA mutations and/or frameshift insert/deletion among 26 oncogenes. Once included in the study, the adenocarcinomas are also included in a Tissue MicroArray (TMA) in order to perform immunohistochemical analysis. Immunohistochemical staining with innovative antibodies are correlated with clinical, histopathological and molecular data.
Our hypothesis is that this TMA could constitute a good tool to screen interesting protein's expression.
|Condition or disease||Intervention/treatment|
|Lung Adenocarcinoma||Genetic: Sequencing|
|Study Type :||Observational|
|Actual Enrollment :||152 participants|
|Official Title:||Molecular Analysis of 150 Lung Adenocarcinoma With Corresponding Histopathological and Clinical Data Available|
|Study Start Date :||January 2014|
|Actual Primary Completion Date :||January 2016|
|Estimated Study Completion Date :||December 2017|
Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.
Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
- Genomic DNA Mutation [ Time Frame: at diagnosis (Day 0) ]Mutations identified by the LungCarta Panel (Sequenom) at the time of diagnosis. DNA was extracted from the lung surgical specimen.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02843711
|Anatomie et cytologie pathologiques Groupement hospitalier Est, Institut de cancérologie des Hospices civils de Lyon,|
|Lyon, France, 69008|
|Principal Investigator:||Marie BREVET, MD||Hospices Civils de Lyon|